Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Simonson PD, Kim KH, Winston-McPherson G, Parakh RS, Yamaguchi D, Merrill AE, et al. Characterization of bilirubin interference in three commonly used digoxin assays. Clin Biochem. 2019;63:102-105.

Ali R, Yang Y, Antkowiak M, Gabr A, Mora R, Abouchaleh N, et al. Prognosticating Survival in Hepatocellular Carcinoma with Elevated Baseline Alpha-fetoprotein Treated with Radioembolization Using a Novel Laboratory Scoring System: Initial Development and Validation. Cardiovasc Intervent Radiol. 2019;42(5):700-711.

Orleans RA, Magro CM, Varghese GI. A subcutaneous nodule on the mid back. JAAD Case Rep. 2019;5(3):252-254.

Karass M, Bareja R, Shelkey E, Vlachostergios PJ, Robinson BD, Khani F, et al. Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer. J Natl Compr Canc Netw. 2019;17(3):194-200.

Gross MD, Awamlh BA, Shoag JE, Mauer E, Banerjee S, Margolis DJ, et al. Race and prostate imaging: implications for targeted biopsy and image-based prostate cancer interventions. BMJ Surg Interv Health Technol. 2019;1(1):e000010.

Crowe EP, DeSimone RA. Transfusion support and alternatives for Jehovah's Witness patients. Curr Opin Hematol. 2019;26(6):473-479.

Zennami K, Choi SM, Liao R, Li Y, Dinalankara W, Marchionni L, et al. PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance. Mol Cancer Res. 2019;17(2):618-627.

Armenia J, Wankowicz SA, Liu D, Gao J, Kundra R, Reznik E, et al. Publisher Correction: The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2019;51(7):1194.

Penchev VR, Chang Y-, Begum A, Ewachiw T, Gocke C, Li J, et al. Ezrin Promotes Stem Cell Properties in Pancreatic Ductal Adenocarcinoma. Mol Cancer Res. 2019;17(4):929-936.

Al-Kawaaz M, Sanchez T, Kluk MJ. Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas. J Hematop. 2019;12(2):57-65.